Allopregnanolone in mood disorders: Mechanism and therapeutic development.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and therapeutic targets without primary empirical data or systematic synthesis.
PubMed 34019980 · doi:10.1016/j.phrs.2021.105682
What was done
This narrative review synthesized preclinical animal research and clinical patient data examining the role of the neuroactive steroid allopregnanolone (ALLO) in mood disorders, including depression, anxiety, and post-traumatic stress disorder. The authors reviewed its molecular mechanisms, interactions with other neurotransmitter systems, and current and emerging therapeutic applications.
What was found
The abstract provides no numerical data, effect sizes, or statistical metrics. It describes ALLO as an endogenous positive allosteric modulator of GABA-A receptors, linking its downregulation to mood disorder pathology alongside interactions with BDNF, dopamine, glutamate, and calcium channels. It notes the clinical approval of intravenous brexanolone for postpartum depression, the ability of SSRIs to reverse ALLO decline, and the emergence of TSPO-targeted synthesis and ALLO derivatives as novel therapeutic directions.
Why it matters
It outlines how neuroactive steroid modulation offers an alternative mechanistic pathway to traditional monoaminergic therapies for treating major depressive and anxiety disorders.
Limits
The abstract describes a broad narrative overview without systematic search criteria, defined inclusion/exclusion filters, or quantitative meta-analysis. No sample sizes, patient demographics, or methodological quality assessments of the underlying studies are provided.
Cited by
- supports 5-alpha reductase inhibitors reduce the synthesis of allopregnanolone, which decreases GABAergic neurosteroid signaling.